Unknown

Dataset Information

0

Durable natural killer cell responses after heterologous two-dose Ebola vaccination.


ABSTRACT: Natural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo (EBOVAC2 consortium, EU Innovative Medicines Initiative), induces NK cell activation and anti-Ebola glycoprotein (GP) antibody-dependent NK cell activation post-dose 1, which is further elevated post-dose 2. Here, in a multicentre, phase 2 clinical trial (EBL2001), we demonstrate durable ex vivo NK cell activation 180 days after dose 2, with responses enriched in CD56bright NK cells. In vitro antibody-dependent responses to immobilised Ebola GP increased after dose 1, and remained elevated compared to pre-vaccination levels in serum collected 180 days later. Peak NK cell responses were observed post-dose 2 and NK cell IFN-? responses remained significantly elevated at 180 days post-dose 2. Individual variation in NK cell responses were influenced by both anti-Ebola GP antibody concentrations and intrinsic interindividual differences in NK cell functional capacity. In summary, this study demonstrates durable NK cell responses after Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccination and could inform the immunological evaluation of future iterations of the vaccine regimen and vaccination schedules.

SUBMITTER: Wagstaffe HR 

PROVIDER: S-EPMC7846750 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


Natural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo (EBOVAC2 consortium, EU Innovative Medicines Initiative), induces NK cell activation and anti-Ebola glycoprotein (GP) antibody-dependent NK cell activation post-dose 1, which is further elevated post-dose 2. Here, in a multicentre, phase 2 clini  ...[more]

Similar Datasets

| S-EPMC8030727 | biostudies-literature
| S-EPMC7324188 | biostudies-literature
| S-EPMC7156503 | biostudies-literature
| S-EPMC6218627 | biostudies-literature
| S-EPMC5328205 | biostudies-literature
| S-EPMC7461885 | biostudies-literature
| S-EPMC5580089 | biostudies-literature
| S-EPMC6036185 | biostudies-literature
| S-EPMC2807462 | biostudies-literature
| S-EPMC1950948 | biostudies-literature